Dermata Therapeutics (NASDAQ:DRMA) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Dermata Therapeutics (NASDAQ:DRMA) released its earnings results on Thursday. The company reported ($1.52) EPS for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.02, FiscalAI reports.

Dermata Therapeutics Stock Performance

Shares of DRMA traded down $0.09 during trading hours on Thursday, hitting $1.37. The company had a trading volume of 201,530 shares, compared to its average volume of 2,189,613. The stock has a market capitalization of $3.89 million, a price-to-earnings ratio of -0.18 and a beta of 0.60. The firm has a fifty day moving average price of $1.64 and a 200-day moving average price of $2.86. Dermata Therapeutics has a 52-week low of $1.11 and a 52-week high of $23.70.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Dermata Therapeutics stock. Clear Street Group Inc. acquired a new position in Dermata Therapeutics, Inc. (NASDAQ:DRMA) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 17,000 shares of the company’s stock, valued at approximately $39,000. Clear Street Group Inc. owned approximately 0.60% of Dermata Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 8.67% of the company’s stock.

Wall Street Analysts Forecast Growth

DRMA has been the topic of several recent research reports. Wall Street Zen cut Dermata Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Dermata Therapeutics in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Dermata Therapeutics has a consensus rating of “Hold” and an average price target of $10.00.

Dermata Therapeutics Company Profile

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.